MLTX vs SVRA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MLTX · MoonLake Immunotherapeutics$11.53 ▲ 6.76%
SVRA · Savara$4.83 ▲ 10.27%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MLTX +6.6%
- SVRA +20.8%
Head to head
| Metric | MLTX | SVRA |
|---|---|---|
| Price | $11.53 | $4.83 |
| Change today | ▲ 6.76% | ▲ 10.27% |
| Market cap | $981.28M | $992.37M |
| Return, 3 months | -33.5% | -15.7% |
| Return, year to date | -12.5% | -19.9% |
| Return, 1 year | +8.5% | +22.3% |
| P/E (TTM) | -3.2 | -8.3 |
| P/B | 2.6 | 6.9 |
| P/E percentile vs own 5y | 90th | 51st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -10.3% | -32.3% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -67.4% | -105.5% |
| Analyst target vs. price | +177.5% | +131.9% |
| Analyst buy share | 88% | 100% |
| RSI (14) | 49 | 51 |
| 30-day volatility | 69.7% | 63.3% |
| Max drawdown, 1 year | -56.9% | -39.2% |
| Trend read | Leaning bearish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SVRA is the largest of the group by market value.
- SVRA has returned the most over the past year.
- SVRA carries the lowest trailing P/E.
- SVRA has been the calmest stock over the last 30 days.